α-Amylase Inhibitory Potential of Antidiabetes Ligands in Spondias Mombin Plant Extract: Molecular Docking and ADMET Profiling

Mary Dada Agoi; Samuel A. Olubode

doi:10.55006/biolsciences.2025.5102

Authors

Mary Dada Agoi Department of Bioscience and Biotechnology, University of Medical Sciences, Ondo city, Ondo State, Nigeria https://orcid.org/0000-0002-5883-8215
Samuel A. Olubode Department of Biochemistry, Adekunle Ajasin University, Akungba Akoko, Ondo State, Nigeria

DOI:

https://doi.org/10.55006/biolsciences.2025.5102

Keywords:

α-amylase, Spondias mombin, Type 2 diabetes, Binding affinity

Abstract

Diabetes mellitus is majorly characterised by hyperglycemia, resulting from the disturbance of glucose homeostasis in the body due to excess calories of dietary sugar. α-amylase enzyme, involved in the digestion of carbohydrate, when inhibited causes a significant reduction in the post-prandial increase of blood glucose, which makes it an important strategy in the management of type 2 diabetes. Literatures have revealed series of compounds from Spondias mombin that exhibited antidiabetes activity. Therefore, this study sought to evaluate the antidiabetic potential of some Spondias mombin compounds using moleculardocking and ADMET profiling. Molecular docking analysis was carried out to study the binding interaction of some phytocompounds; Chlorogenic acid, Zeinoxanthin, Lutein, Isoquercetin, Quercetin, Rutin, Rhamnetin and Rutinose from Spondias mombin against α-amylase via Maestro 2017. Following the selection of the top five molecules, their bioavailability, drug-likeness, pharmacokinetic properties and toxicity were evaluated using the swissadme and protox iii webserver. Rhamnetin (-8.0 kcal/mol), quercetin (-7.8 kcal/mol), rutin (-7.9 kcal/mol), isoquercetin (-8.4 kcal/mol) and chlorogenic acid (-7.8 kcal/mol) gave higher docking score against α-amylase than the standard drug, acarbose (-7.2 kcal/mol). Quercetin and Rhamnetin also demonstrated high bioavailability, drug-likeness, pharmacokinetic properties and less toxicity. This study therefore uncovers potential α-amylase inhibitors in Spondias mombin with better binding affinities than acarbose and good ADMET properties, which may then serve as potential drug candidates for the management of diabetes. However, pharmacophore modelling is proposed in furtherance of this findings to identify possible variations of binding affinities with modification in their properties.

Downloads

Download data is not yet available.

Author Biography

Mary Dada Agoi, Department of Bioscience and Biotechnology, University of Medical Sciences, Ondo city, Ondo State, Nigeria

*Corresponding Author

References

1. Fred-Jaiyesimi A, Abo K. Antidiabetic Activity of Spondias mombin Extract in NIDDM Rats. Pharmaceutical Biology. 2009;47(3): 215-218.

2. Gbolade AA. Effects of Spondias mombin stem bark and Senna alata leaf extracts on some biochemical parameters in rats”.Journal of Pharmacy & Bioresources.2010;7(1): 1-8.

3. Gobinath R, Parasuraman S, Sreeramanan, S., Enugutti, B. and Chinni, S. V. Antidiabetic and Antihyperlipidemic Effects of Methanolic Extract of Leaves of Spondias mombin in Streptozotocin Induced Diabetic Rats”. Frontiers in Physiology.2022;13:870399.

4. KhanTA, Sievenpiper J.L. Controversies about sugars: Results from systematic reviews and metaanalyses on obesity, cardiometabolic disease and diabetes. European Journal of Nutrition. 2016;55: S25S43.

5. Omoboyowa DA. Exploring molecular docking with E-pharmacophore and QSAR models to predict potent inhibitors of 14α-demethylase protease from Moringa spp. Pharmacological Research -Modern Chinese Medicine.2022;4: 100147.

6. Osuntokun OT. Exploring the Medicinal Efficacy, Properties and Therapeutic uses of Spondias mombin (Linn)”. International Journal of Applied Research on Medicinal Plants.2019;2: 115-120.

7. Skyler JS. “Diabetes Mellitus: Pathogenesis and treatment strategies”. Journal of Medicinal Chemistry.2004;47: 4113 411747.

8. Sun H, SaeediP, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2022;183:109119.

9. Omoboyowa DA, Agoi MD, Shodehinde SA, Saibu OA, Saliu JA. Anti-diabetes Effects of Solvent-Partitioned Fractions of Spondias mombin (Linn) Stem Bark in High–Sucrose Diet Induced Drosophila melanogaster Model. Journal of Taibah University Medical Sciences, 2023;18(4):663–675.

10. Ajiboye BO, Ojo OA, Okesola MA, Akinyemi AJ, Talabi JY, Idowu OT. In vitro antioxidant activities and inhibitory effects of phenolic extract of Senecio biafrae (Oliv and Hiern) against key enzymes linked with type II diabetes mellitus and Alzheimer's disease. Food Science & Nutrition. 2018;6(7):1803–10.

11. Trott O, Olson AJ. Autodock Vina: improving the speed and accuracy of docking with new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry.2010;2: 455–461.

12. Omoboyowa DA, Omomule OM, Balogun TA, Saibu OA, Metibemu DS. Protective potential of ethylacetate extract of Abrus precatorius seeds against HCl/EtOH-induced gastric ulcer via pro-inflammatory regulation: in vivo and in silico studies. Phytomedicine Plus. 2021;1(3):100-145.

13. Sofela SO, Bodun DS, Omoboyowa AD, Ajiboro AD, Nwankwo DO, Ashimiyu-Abdusalam Z, Isaac BI, Abdulrasheed B, Balogun TA, Ajayi IH. Virtual screening for novel FGFR2 inhibitors: Exploring Gefitinib-like compounds as promising therapeutic candidates. Informatics in Medicine Unlocked. 2023; 42(3):101368.

14. Ajiboye BO, Fagbola TM, Folorunso IM, Salami AW, Aletile ON, Akomolede BA, Ayemoni FI, Akinfemiwa KI, Anwo VO, Ojeleke MI, Oyinloye BE. In silico identification of chemical compounds in Spondias mombin targeting aldose reductase and glycogen synthase kinase 3β to abate diabetes mellitus. Informatics in Medicine Unlocked. 2023;36(101126):2352-9148.

15. Boadu A, Agoni C, Karpoormath R. Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors. Scientific Reports. 2022;12(1):10896.

16. Olanrewaju JA, Arietarhire LO, Soremekun OE, Olugbogi EA, Afolabi TO, Aribisala PO, Alege PE, Sodipo AO, Oyinloye BE, Omotuyi OI. Spondias mombin flavonoids showed super-binder ability with downstream molecular targets of Parkinson's disease: A structural study. Informatics in Medicine Unlocked. 2024;49(101543):2352-9148.

17. RampoguS, Baek A, ZebA, Lee KW. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations, BMC Cancer. 2018;18(1): 264.

18. Aini NS, Kharisma VD, Widyananda MH, Murtadlo AAA, Probojati RT, Turista DDR, Zainul R. In silico screening of bioactive compounds from Syzygium cumini L. and moringa oleifera L. against SARS-CoV-2 via tetra inhibitors. Pharmacognosy Journal. 2022;14(4):267-272.

19. Kumar, A., Kalra, S., Jangid, K. and Jaitak, V. Flavonoids as P-glycoprotein inhibitors for multidrug resistance in cancer: an in-silico approach. Journal of Biomolecular Structure and Dynamics. 2022;1–13.